2LPAPI® is developed by Labo'Life.

What development phase is 2LPAPI® in?

2LPAPI® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

2LPAPI®

Labo'Life · FDA-approved active Small molecule Quality 4/100

2LPAPI®, marketed by Labo'Life, is a therapeutic agent with a unique mechanism of action targeting a specific bodily function, though its primary indication and revenue figures are not specified. The drug's key strength lies in its patented composition, which is protected until 2028, providing a significant barrier to generic competition. However, the lack of detailed clinical trial results and identified competitors poses a primary risk, potentially limiting its market penetration and strategic positioning.

At a glance

Generic name	2LPAPI®
Also known as	2LPAPI
Sponsor	Labo'Life
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

2LPAPI® CI brief — competitive landscape report
2LPAPI® updates RSS · CI watch RSS
Labo'Life portfolio CI